ReviewExpert reviews in molecular medicine2008
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.
Review in Expert reviews in molecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.Viral immunology · 2010Pooled it
- Article
- Integrated Laboratory Evaluation of Rift Valley Fever Virus Antibodies Using the Competitive ELISA and Virus Neutralization Test.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Molecular diagnosis of arboviruses (dengue, Chikungunya, yellow fever, Rift Valley fever, Mayaro, West Nile, and Zika viruses) in non-malaria acute febrile illnesses in Kenya's Garissa County, July 2023, and Mombasa County, July 2024.BMC infectious diseases · 2026Article
- Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program.Frontiers in immunology · 2026Review
- Review
- Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate.PLoS pathogens · 2024Article
- Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.Journal of virology · 2024Article
- Protection against symptomatic dengue infection by neutralizing antibodies varies by infection history and infecting serotype.Nature communications · 2024Article
- Defining the "Correlate(s) of Protection" to tick-borne encephalitis vaccination and infection - key points and outstanding questions.Frontiers in immunology · 2024Review
- Identification of an immunodominant region on a group AVirulence · 2023Article
- Homotypic antibodies target novel E glycoprotein domains after natural DENV 3 infection/vaccination.Cell host & microbe · 2023Article
- Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.NPJ vaccines · 2023Article
- A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.Frontiers in immunology · 2023Article
- Tick-borne encephalitis vaccine effectiveness and barriers to vaccination in Germany.Scientific reports · 2022Article
- Are the Organoid Models an Invaluable Contribution to ZIKA Virus Research?Pathogens (Basel, Switzerland) · 2021Review
- Substantial Attenuation of Virulence of Tembusu Virus Strain PS Is Determined by an Arginine at Residue 304 of the Envelope Protein.Journal of virology · 2021Article
- Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors.Small methods · 2021Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Flaviviruses are a group of positive-stranded RNA viruses that cause a spectrum of severe illnesses globally in more than 50 million individuals each year. While effective vaccines exist for three members of this group (yellow fever, Japanese encephalitis, and tick-borne encephalitis viruses), safe and effective vaccines for several other flaviviruses of clinical importance, including West Nile and dengue viruses, remain in development. An effective humoral immune response is critical for protection against flaviviruses and an essential goal of vaccine development. The effectiveness of virus-specific antibodies in vivo reflects their capacity to inhibit virus entry and spread through several mechanisms, including the direct neutralisation of virus infection. Recent advances in our understanding of the structural biology of flaviviruses, coupled with the use of small-animal models of flavivirus infection, have promoted significant advances in our appreciation of the factors that govern antibody recognition and inhibition of flaviviruses in vitro and in vivo. In this review, we discuss the properties that define the potency of neutralising antibodies and the molecular mechanisms by which they inhibit virus infection. How recent advances in this area have the potential to improve the development of safe and effective vaccines and immunotherapeutics is also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.